Biomed Res Int
doi: 10.3389/fnut.2026.1778473 Received 31 December 2025 Revised 09 March 2026 Accepted 26 March 2026 Published 28 April 2026 Volume 13 - 2026 Edited by Huanling Lai, Guangzhou National Laboratory, China Reviewed by Jiayi Zhou, University of North Carolina at Chapel Hill, United States Mairepaiti Halimulati, The University of Texas at Austin, United States Updates Copyright 2026 Sun, Sun, Nan, Wang, Sun, Shi, Yang and Wang
Tell us your population of interest and endpoints
Regular physical activity, consistent sleep patterns, adequate protein intake, and stress management accelerate weight loss outcomes
Tirzepatide (Zepbound ) Injection (Commercial Product by Eli Lilly Company) Tirzepatide Description 1-4 Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
B.MinK.TalbertE